Stem Cell Therapy in Diabetes Mellitus

Abstract

The loss of pancreatic cells characterises type 1 diabetes mellitus (T1DM), the most prevalent chronic autoimmune illness in young individuals. As a result, the body lacks insulin and becomes hyperglycemic. Exogenous insulin cannot replace the endogenous insulin secreted by a healthy pancreas through administration or injection. For restoring the normal regulation of blood glucose in T1DM patients, pancreas and islet transplantation have shown promise. The broad use of these techniques is hindered by a significant shortage of pancreases and islets obtained from human organ donors, transplantation-related difficulties, a high cost, and limited procedural accessibility. There have been initiatives to handle the rising number of T1DM patients. With stem cell therapy, T1DM patients have a high probability of recovery. There have been advancements in stem cell-based therapies for T1DM with the development of research on stem cell treatment for a variety of disorders.